Author: Ravi Shankar

iPhone 18 Pro and iPhone Duo launch with Anterix 900 MHz connectivity, extending dedicated private wireless to one of the world’s most widely used device platforms

WOODLAND PARK, N.J., Sept. 21, 2026 (GLOBE NEWSWIRE) — Anterix (NASDAQ: ATEX), the market leader in enabling mission-critical private wireless broadband networks, today announced that the new iPhone 18 Pro and iPhone Duo are the first iPhone models to operate on dedicated private LTE networks using Anterix 900 MHz spectrum.

The new models bring iPhone connectivity to dedicated private wireless networks operating on band 106 licensed 900 MHz spectrum, giving critical infrastructure operators another device for field communications, operational applications, video, situational awareness and other mission-critical activities.

“When we started down this path, private wireless was a very different market,” said Carlos L’Abbate, Chief Technology and Engineering Officer of Anterix. “Today, an iPhone, which is used every day by millions of people, can now operate on the same private 900 MHz network infrastructure that supports mission-critical operations. It is another clear sign that dedicated private wireless networks are becoming mainstream communications platforms.”

Private wireless networks connect the people, equipment and applications that critical infrastructure operators rely on every day. With iPhone now supported on Anterix 900 MHz Band 106 networks, operators can incorporate a widely used mobile device into the same dedicated network infrastructure supporting specialized devices and operational systems across their environments.

Anterix Shareholder Contact
Natasha Vecchiarelli
VP, Investor Relations & Corporate Communications
nvecchiarelli@anterix.com

Media Contact
Kristin Ford-Glencross for Anterix
anterix@antennagroup.com

About Anterix

Anterix is transforming how critical infrastructure stays connected. As the market leader in mission-critical private wireless broadband spectrum, Anterix delivers more secure, private 900 MHz licensed spectrum and advanced intelligent infrastructure solutions that enhance efficiency, strengthen resilience, and accelerate digital transformation. Backed by a growing ecosystem of industry-leading partners, Anterix provides the connectivity foundation that powers a more resourceful and resilient future. Learn more at www.anterix.com.

MONTREAL, Sept. 21, 2026 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) today launched its annual Rail Safety Week campaign to raise awareness about the risks of unsafe behaviour around railway tracks and property.

From September 21-27, CN Police Services and CN employees will be engaging with communities across North America to mark Rail Safety Week and reinforce a simple but critical message: safety around railway tracks and crossings is a shared responsibility. Together they will work to raise awareness about the dangers of trespassing on railway property and ignoring signals at crossings. These unsafe behaviors can have devastating consequences, but they are also preventable when we all do our part.

“Every crossing and every set of tracks deserves your full attention. The vast majority of rail incidents are preventable, that’s why every safe choice we make around trains and tracks can save lives. Rail safety is a shared responsibility, and together we can protect our families, friends and communities.”

  – Shawn Will, Chief of Police and Chief Security Officer, CN 

The statistics are striking: North America sees over 2,000 crossing accidents and 1,000 trespassing incidents annually. In Canada alone, 2025 recorded 252 such incidents, resulting in 69 fatalities and 60 serious injuries. These numbers underscore the critical need for continued education and awareness.

Rail Safety is a Shared Responsibility
CN is committed to doing its part to keep its network and the communities it travels through safe. That means investing in safe railway operations, working closely with communities and first responders, and supporting education and enforcement efforts that help reduce unsafe behaviour around tracks and crossings.

But rail safety extends beyond the railway. Drivers, pedestrians, cyclists and community partners all have a role to play. Staying off railway tracks and property, obeying crossing signals and never attempting to beat a train are simple choices that can save lives.

For more than two decades, CN has worked with communities to champion rail safety. In 2025, more than 403 municipalities across North America formally recognized Rail Safety Week through resolutions and proclamations. This year, we are once again asking our community partners to help amplify this important message and encourage safe behaviour around railways.

About CN Police
Every year, CN Police Services respond to hundreds of incidents along CN’s network, which spans eight Canadian provinces and 16 U.S. states. In addition to protecting CN property, CNPS officers deliver rail safety presentations to schools, trucking agencies, bus operators and community organizations. By rolling out strategic educational initiatives and conducting targeted operations, CNPS aims to promote safe behaviours and increase awareness of the need for rail safety. CNPS is committed to making CN the safest railroad in North America.

About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.

For more information or to schedule an interview with CN Police, contact:

Alberta
Atlantic
British Columbia
Manitoba
Ontario
Quebec
Saskatchewan
Canada

Contacts:

Media

Ashley Michnowski

Senior Manager

Media Relations

(438) 596-4329

media@cn.ca

REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company’s President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company.

Charles Endweiss, who has been Seer’s Vice President, Financial Planning & Analysis, will serve as Treasurer, principal financial officer and principal accounting officer, effective October 1, 2026.

“David has been an important member of Seer’s leadership team for more than six years, helping guide the Company through a pivotal period,” said Omid Farokhzad, M.D., Chair and Chief Executive Officer of Seer. “We are grateful for David’s many contributions and wish him all the best in his next chapter.”

Dr. Farokhzad added, “Charles has been a trusted member of Seer’s finance organization for nearly five years and brings the financial expertise, leadership and deep understanding of our business that are critical to our continued progress. We are confident he will play an important role in continuing our efforts to position Seer for long-term success.”

“It has been a privilege to work alongside Omid and the entire Seer team over the past six years,” said Mr. Horn. “I am proud of what we have accomplished together and remain confident in the team, Seer’s differentiated technology and the opportunity ahead for the Company. I have worked closely with Charles Endweiss and am confident he will be a strong steward of the finance team. I look forward to following the Company’s continued success.”

About Charles Endweiss
Charles Endweiss, age 49, has served as the Company’s Vice President, Financial Planning & Analysis since January 2021. Prior to joining the Company, Mr. Endweiss served as Head of Business Operations, Oral Health at Carbon, a provider of end-to-end digital 3D printing and manufacturing platform, from August 2017 to January 2021. Earlier in his career, Mr. Endweiss held a range of accounting, finance, and business operations positions at various technology companies. He holds a B.A. in Business from the University of Illinois, Urbana-Champaign and an M.B.A. from Santa Clara University.

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph^® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements relating to the transition in finance and accounting roles at the Company. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych
investor@seer.bio

Firm, contracted power for up to 207 MW gives New Era control of Phase 1 power

Companion development framework establishes a pathway for future expansion of the site

MIDLAND, Texas, Sept. 21, 2026 (GLOBE NEWSWIRE) — New Era Energy & Digital, Inc. (Nasdaq: NUAI) (“New Era” or the “Company”), a developer of next-generation digital infrastructure and integrated power assets, today announced that its subsidiary, TCDC PowerCo LLC, has entered into a 20-year power purchase agreement with Luminant ET Services Company LLC (“Luminant”), an affiliate of Vistra Corp. (“Vistra”, NYSE: VST), under which Luminant has agreed to supply a minimum of 200 MW and up to 207 MW of power for Phase 1 of New Era’s Texas Critical Data Center (“TCDC”) project.

Under the PPA, Luminant will supply power from Vistra’s 1,180 MW natural gas-fired generating facility in Odessa, Texas, which is located immediately adjacent to the TCDC site. The PPA has an initial 20-year term, with automatic one-year renewal periods thereafter. The firm, contracted power is expected to be available to TCDC in Q3 of 2027.

“Having firm, contracted power for Phase 1 in New Era’s name is an incredible milestone which we believe materially reduces Phase 1 development risk at TCDC,” said Charlie Nelson, Chairman and Chief Executive Officer of New Era. “We said last month that holding this power ourselves is what would turn TCDC from a site with a power plan into permitted powered land. That is what this agreement is intended to do. With the land secured, construction permits in hand, Phase 1 power contracted for 20 years, and room to expand to multiple phases, we believe this is an attractive opportunity to any quality tenant currently in the market.”

“Combining this PPA with a long-term partnership with Vistra is something of which we are particularly proud. We believe aligning our interests will expedite development timelines and give potential tenants confidence in our project.”

Development Framework Agreement Expands Relationship Beyond Phase 1

Concurrently with the PPA, affiliates of New Era and Vistra entered into a development framework agreement that establishes a pathway for advancing future power development at TCDC and other New Era projects. Following commencement of power delivery, Vistra will receive a 5% non-voting interest in the portion of the data center project to which Vistra provides power under the PPA. The agreement also provides Vistra with a right of first refusal on future development opportunities at the TCDC project and, a right of first offer on certain development opportunities serving other New Era projects.

“Demand for reliable power to support digital infrastructure continues to grow across the United States,” said Claudia Morrow, Senior Vice President of Corporate Development and Strategy at Vistra. “We are pleased to work with New Era on a long-term power arrangement for the TCDC project and to establish a framework that allows us to evaluate additional power opportunities together over time.”

About New Era Energy & Digital, Inc.

New Era Energy & Digital is developing large-scale data centers across energy-rich U.S. markets to support AI training and inference workloads. New Era’s flagship project, Texas Critical Data Centers, is a 493-acre site located in the Permian Basin, with anticipated capacity scaling to 1.4 GW over time. New Era’s strategy is to combine large-acreage sites with flexible power solutions, including behind-the-meter power. New Era’s approach is a modular, phased data center deployment model, utilizing best-in-class water efficiency and self-generated power to minimize community impact and accelerate time-to-power for hyperscale, enterprise and edge operators.

For more information, visit: www.newerainfra.ai and follow New Era Energy & Digital on LinkedIn and X.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook, including our ability to obtain credit support on commercially reasonable terms or at all, and, if obtained, to keep such credit support in place. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: our ability to construct, develop, lease and maintain our flagship project; our ability to realize the anticipated benefits of the power purchase agreement; our ability to access adequate project financing, commercial borrowings and debt and equity capital markets to fund our significant anticipated capital expenditures; the ability to obtain credit support to secure contractual obligations on commercially reasonable terms or at all; the impact of supply chain disruptions, labor availability, raw materials and input commodity costs and availability, and manufacturing and transportation; general business and economic conditions; environmental history, remediation, and associated risks; our ability to obtain and renew leases with our tenants on terms favorable to us, and manage our growth, business, financial results and results of operations; our ability to respond to price fluctuations and rapidly changing technology; the impact of tariffs and global trade disruptions on us and our tenants; changes in political conditions, geopolitical turmoil, political instability, civil disturbances, and restrictive governmental actions; the degree and nature of our competition; our failure to generate sufficient cash flows to service indebtedness; our expectations regarding the anticipated timeline of our cash, cash equivalents and short-term investments, future financial performance and our ability to continue as a going concern; material negative changes in the creditworthiness and the ability of our tenants to meet their contractual obligations; increases and volatility in interest rates; increased power, labor, equipment procurement, shipping, refurbishment or construction costs; a failure of our information technology systems, systems conversions and integrations, cybersecurity attacks or a breach of our information security systems, networks or processes; our inability to obtain and/or maintain necessary government or other required consents or permits; changes in, or the failure or inability to comply with, local, state, federal and applicable international laws and regulations, including related to taxation, real estate and zoning laws, and increases in real property tax rates; the impact of any financial, accounting, legal or regulatory issues or litigation that may affect us; our ability to maintain an effective system of disclosure controls and procedures and internal control over financial reporting and operations; and other factors (including the risks contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our Form 10-Q for the quarterly period ended June 30, 2026). Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

For investor inquiries, please contact:

OG Advisory Group
Lincoln Tan
nuai@orangegroupadvisors.com

The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted

Ninety-seven percent of care partners reported that agitation negatively impacted their loved one’s quality of life, and three in four wish they had recognized symptoms sooner

Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana

Survey conducted by The Harris Poll and in collaboration with CaringKind

NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer’s Day, announced results of the Shared Goals: Navigating Alzheimer’s Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer’s disease and their family care partners.

The Shared Goals survey of 751 adults who currently provide care to a loved one with Alzheimer’s disease was conducted online by The Harris Poll, with input from CaringKind, a leading expert on Alzheimer’s and dementia caregiving with over 40 years of experience, and sponsored by Axsome. It is among the largest and most recent surveys of care partners of people living with Alzheimer’s disease agitation. The Shared Goals survey results were presented at Psych Congress 2026 in New Orleans, Louisiana, on September 17 and 18, 2026.

“These survey findings give important insights into why there is such a delay in recognition of symptoms of agitation. Because the behaviors doing the most damage can be mistaken for personality changes or disease progression, they often go unaddressed until daily life is significantly disrupted,” said Brent P. Forester, M.D., psychiatrist-in-chief and chair of the Department of Psychiatry at Tufts Medical Center and director of Behavioral Health for Tufts Medicine. “Recognizing these behaviors early and discussing them with a healthcare provider allows families and clinicians to set shared goals for care and discuss treatment options, which may help them manage agitation before it becomes too overwhelming to them.”

Care partners surveyed reported that agitation negatively affected their loved one’s overall quality of life (97%), ability to care for themselves (96%), community engagement (95%) and maintaining relationships with family and friends (89%). While 85% of care partners reported being highly involved in treatment decisions, recognition often comes too late, with 76% wishing they had recognized symptoms of agitation sooner and 53% regretting not talking to their loved one’s healthcare provider sooner about their agitation symptoms.

The survey also revealed that the symptoms of Alzheimer’s disease that are most detrimental to a loved one’s overall quality of life are nonaggressive symptoms of agitation, such as complaining, negativism, frequent unwarranted requests for help (76%); repetitive sentences or questions, inappropriate laughter or crying (75%); repetitive mannerisms (67%); and pacing or aimless wandering (56%).  

Care partners also expressed a desire for resources to help manage their loved ones’ symptoms of agitation: 89% wished they had an easier way to track their loved one’s symptoms of agitation over time, and 81% expressed interest in a way to easily and discreetly share information about such symptoms with their loved ones’ doctor. Care partners also described unmet needs in managing agitation, with nearly half (47%) worried if they are making the right medication decisions for their loved ones. Further, 93% of care partners said they wish there was a medication that reduced their loved one’s symptoms of agitation without adding negative side effects.

Additional survey results and more information on Alzheimer’s disease agitation can be found by visiting ALZGoals.com.  

Survey Methodology

The Harris Poll, on behalf of Axsome Therapeutics, Inc., conducted an online survey among 751 adults age 18+ in the U.S. who currently provide informal (i.e., unpaid or unprofessional) care to a loved one with Alzheimer’s disease, between October 7 – 28, 2025. For complete survey methodology, including weighting variables, sample definition/details, subgroup sample sizes, and credible interval, please contact medinfo@axsome.com.

About Agitation Associated with Dementia Due to Alzheimer’s Disease

Alzheimer’s disease is the most common form of dementia affecting more than 7 million people in the U.S.¹ Agitation associated with dementia due to Alzheimer’s disease is a neuropsychiatric condition reported in up to 75% of patients with Alzheimer’s disease and is characterized by emotional distress, verbal and physical aggressiveness, disruptive irritability and disinhibition.^1,2 The exact cause of agitation in the brain is not known but it is associated with changes in glutamate and monoamine signaling.^3,4 Agitation has been associated with accelerated cognitive decline, increased caregiver burden and increased mortality risk and is a leading cause of assisted living or nursing home placement.⁵

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for agitation associated with dementia due to Alzheimer’s disease, major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

References:

1. Alzheimer’s Disease Facts and Figures. Alzheimer’s Association. July 22, 2026. https://www.alz.org/alzheimers-dementia/facts-figures.
2. Van der Mussele S, Le Bastard N, Saerens J, et al. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer’s dementia. Aging Ment Health. 2015;19(3):247-257.
3. Cummings JL, Brubaker M, Selzler KJ, Gonzalez ST, Patel M, Stahl SM. An overview of the pathophysiology of agitation in Alzheimer’s dementia with a focus on neurotransmitters and circuits. CNS Spectr. 2024;23:1-10.
4. Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits? Mol Aspects Med. 2015;43-44:25-37.
5. Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother. 2017;18(6):611-620.

BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has completed their last visit in the Company’s Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

The randomized, double-blind, placebo-controlled Phase 2a trial, known as INFORM-MS (NCT06292923), enrolled a total of 48 patients across three cohorts at multiple leading U.S. clinical sites. The study is evaluating the safety, tolerability, and efficacy of two doses of intranasal foralumab versus placebo over a 12-week treatment period, with the primary endpoint focused on change in microglial activation as measured by positron emission tomography (PET) imaging, along with secondary clinical endpoints including the Expanded Disability Status Scale (EDSS) and the Modified Fatigue Impact Scale (MFIS). Tiziana expects to lock the database this week, and announce 12-week treatment topline data in October.

Following completion of the blinded phase, all participants, including those who initially received placebo, have the opportunity to receive intranasal foralumab in a six-month follow on open-label extension (OLE). The OLE is designed to generate longer term safety and efficacy data. Encouragingly, data from the Company’s Expanded Access Program in na-SPMS have shown that most patients treated with intranasal foralumab either stabilized or improved in clinical outcomes over an extended treatment duration.

“I congratulate the entire Tiziana team, our clinical investigators, study sites, and most importantly the patients and their families who made this milestone possible,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “Completing the last patient last visit in our Phase 2a INFORM-MS trial is a significant achievement. The dedication and hard work of everyone involved have brought us to this important point in the development of intranasal foralumab for patients living with na-SPMS, a condition with unmet medical need. We look forward to unblinding and presenting the topline data next month.”

About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923), as well as additional Phase 2 trials in AD and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and include statements regarding the closing of the Offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

To the Nasdaq Copenhagen

21 September 2026

Debtor distribution data (CK92)

Pursuant to s 24 Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes debtor distribution data for callable mortgage bond series as at 18 September 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/filarkiv/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Nykredit Realkredit A/S

Attachments

• Debtor distribution data – Nykredit Realkredit A_S 21-09-2026
• debisams_21092026

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	18th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	35,703	282	281.5
Ordinary shares	Sales	515,471	282	281.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	21st September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Methanex Corporation (the “Company” or “Methanex”) (TSX: MX) (Nasdaq: MEOH) announced today that it has issued a notice of partial redemption for US$300 million of its outstanding 5.125% senior notes due October 15, 2027. The redemption date is October 19, 2026.

Rich Sumner, President and CEO, Methanex Corporation, stated, “Today’s announcement is underpinned by the company’s strong cash position and cash flow generation capability, resulting from continued tight global methanol market conditions combined with production from our significantly strengthened asset base, and is aligned with our commitment to progress towards our stated balance sheet leverage target.”

ABOUT METHANEX

Methanex is a Vancouver-based, publicly traded company and is the world’s largest supplier of methanol globally. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol “MX” and on the Nasdaq Stock Market in the United States under the trading symbol “MEOH”. Methanex can be visited online at www.methanex.com.

FORWARD-LOOKING INFORMATION WARNING

This news release contains certain forward-looking statements, or forward-looking information, with respect to us and our industry. These statements relate to future events or our future performance. All statements other than statements of historical fact are forward-looking statements. Statements that include the word “will” or other comparable terminology and similar statements of a future or forward-looking nature identify forward-looking statements.

Forward-looking statements, by their nature, involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Factors that may cause actual results to vary include, but are not limited to, risks relating to conditions in the financial markets and other risk factors as detailed from time to time in Methanex’s reports filed with Canadian securities administrators and the U.S. Securities and Exchange Commission. Certain of these risks are described in more detail in our 2025 Annual Management’s Discussion and Analysis and Second Quarter 2026 Management’s Discussion and Analysis and in our public filings with Canadian securities administrators and the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on forward-looking statements. They are not a substitute for the exercise of one’s own due diligence and judgment. The outcomes implied by forward-looking statements may not occur and we do not undertake to update forward-looking statements except as required by applicable securities laws.

Inquiries:
Robert B. Winslow, CFA
Vice President, Investor Relations
Methanex Corporation
604-661-2600 or Toll Free: 1-800-661-8851
www.methanex.com

• Strategic collaboration accelerates Einride’s push into highway and suburban autonomous trucking.
• Einride will adapt the NVIDIA DRIVE Hyperion platform for heavy-duty trucking, working directly with NVIDIA to extend the platform’s compute, sensor, software and safety architecture to the demands of heavy-duty freight.
• Building the next generation of the Einride Driver on NVIDIA Hyperion platform, will enable Einride to scale autonomous deployment across a freight network that’s already serving customers today.

STOCKHOLM, Sept. 21, 2026 (GLOBE NEWSWIRE) — Einride AB (Nasdaq: ENRD) (“Einride” or the “Company”), a technology company driving the transition to cost-efficient autonomous and electric freight for some of the world’s largest shippers, today announced a collaboration with NVIDIA to further accelerate the transition of the Company’s extensive freight network to autonomous operations.

Einride develops and integrates the technologies required to create cost-efficient autonomous and electric freight networks for its global shipping customers. Einride currently operates hundreds of electric trucks for major shippers across the U.S., Europe, and the Middle East, including autonomous trucks already operating in contracted customer deployments. This footprint is expected to scale to 1,500-2,000 vehicles by 2028, based on customer demand captured on its platform so far, and approximately 80% of that demand is suitable for automation in the medium term as the company continues to advance its autonomous technology.

Einride designs, builds, and operates the autonomous-driving system end-to-end, including safety validation, regulatory approval, and contracted customer deployments, while NVIDIA provides the underlying compute platform and AI development tools that support the system.

“We have the customers, the operational experience and the technology. Building the next generation of the Einride Driver on the NVIDIA Hyperion platform, will enable us to scale autonomous deployment across a freight network that’s already serving customers today,“ said Henrik Green, Chief Technology Officer at Einride.

“Autonomous trucking represents one of the clearest opportunities to improve the safety and efficiency of global freight,” said Rishi Dhall, vice president of automotive at NVIDIA. “By building on NVIDIA Hyperion with the NVIDIA Halos safety system and using NVIDIA Cosmos and Blackwell infrastructure, Einride can accelerate the development and validation of its autonomous-driving technology and scale deployments across its growing freight network.”

Built on the NVIDIA Hyperion platform, a production-ready compute and sensor reference architecture for Level 4 autonomy, and integrated with the NVIDIA Halos safety system, the collaboration creates a scalable foundation that accelerates safe, production-ready autonomous freight operations for Einride.

Einride intends to deploy NVIDIA Blackwell architecture at scale with an NVIDIA Exemplar Cloud partner, a cloud provider whose infrastructure NVIDIA has validated for large-scale AI training performance, to train, test and refine its autonomous driving models. This is a compute and development infrastructure that supports Einride’s own autonomous-driving stack.

Einride will adapt the NVIDIA Hyperion platform for heavy-duty trucking, working directly with NVIDIA to extend the platform’s compute, sensor, software and safety architecture to the demands of heavy-duty freight. As part of its AI development workflow, Einride is using NVIDIA Cosmos to help improve the safety and reliability of its autonomous vehicles. NVIDIA Cosmos enables Einride to search and curate camera data to identify complex edge cases, as well as augment real-world data with photorealistic synthetic scenarios that increase the diversity of data used for AI training and validation.

About Einride

Founded in Stockholm in 2016, Einride (Nasdaq: ENRD) is a technology leader driving the transition to sustainable, cost-efficient autonomous and electric freight operations. The company’s platform integrates AI-powered freight intelligence, proprietary autonomous technology, and one of the world’s largest electric heavy-duty fleets. Einride serves a global customer base across North America, Europe, and the Middle East through a dual business model encompassing Freight-Capacity-as-a-Service (FCaaS) and a software platform.

Investor & Media Contacts
Christina Zander
Head of Communications, Einride
press@einride.tech, einride@icrinc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/967e7af8-18f2-499b-81de-182b68ded31f